Susquehanna International Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-145,890
| Closed | -$8.57M | – | 13833 |
|
|
2023
Q4 | $8.57M | Sell |
145,890
-137,501
| -49% | -$7.73M | ﹤0.01% | 2847 |
|
|
2023
Q3 | $12.3M | Buy |
283,391
+58,290
| +26% | +$2.08M | ﹤0.01% | 2291 |
|
|
2023
Q2 | $8.13M | Sell |
225,101
-137,511
| -38% | -$5.67M | ﹤0.01% | 2789 |
|
|
2023
Q1 | $13.5M | Buy |
362,612
+294,921
| +436% | +$13.3M | ﹤0.01% | 2108 |
|
|
2022
Q4 | $3.07M | Sell |
67,691
-12,088
| -15% | -$782K | ﹤0.01% | 3979 |
|
|
2022
Q3 | $5.57M | Buy |
79,779
+76,799
| +2,577% | +$5.68M | ﹤0.01% | 2990 |
|
|
2022
Q2 | $200K | Sell |
2,980
-38,316
| -93% | -$2.44M | ﹤0.01% | 10636 |
|
|
2022
Q1 | $3.4M | Buy |
41,296
+3,688
| +10% | +$377K | ﹤0.01% | 4389 |
|
|
2021
Q4 | $5.52M | Sell |
37,608
-50,976
| -58% | -$7.91M | ﹤0.01% | 3571 |
|
|
2021
Q3 | $15.7M | Buy |
88,584
+25,775
| +41% | +$4.15M | ﹤0.01% | 2265 |
|
|
2021
Q2 | $10.1M | Buy |
62,809
+9,605
| +18% | +$1.54M | ﹤0.01% | 2902 |
|
|
2021
Q1 | $9.11M | Buy |
53,204
+40,961
| +335% | +$8.11M | ﹤0.01% | 2924 |
|
|
2020
Q4 | $2.69M | Buy |
12,243
+1,624
| +15% | +$351K | ﹤0.01% | 4502 |
|
|
2020
Q3 | $1.76M | Buy |
10,619
+2,757
| +35% | +$377K | ﹤0.01% | 4873 |
|
|
2020
Q2 | $898K | Sell |
7,862
-12,060
| -61% | -$1.17M | ﹤0.01% | 6164 |
|
|
2020
Q1 | $1.53M | Sell |
19,922
-30,948
| -61% | -$2.78M | ﹤0.01% | 4458 |
|
|
2019
Q4 | $6.55M | Buy |
50,870
+27,278
| +116% | +$2.63M | ﹤0.01% | 2597 |
|
|
2019
Q3 | $1.84M | Sell |
23,592
-81,053
| -77% | -$7.61M | ﹤0.01% | 4385 |
|
|
2019
Q2 | $10.8M | Buy |
104,645
+59,869
| +134% | +$4.66M | ﹤0.01% | 1804 |
|
|
2019
Q1 | $3.28M | Buy |
+44,776
| New | +$3.05M | ﹤0.01% | 3005 |
|
|
2018
Q2 | – | Sell |
-47,189
| Closed | -$1.78M | – | 10633 |
|
|
2018
Q1 | $1.45M | Buy |
+47,189
| New | +$1.31M | ﹤0.01% | 4508 |
|
|
2017
Q4 | – | Sell |
-46,870
| Closed | -$727K | – | 10075 |
|
|
2017
Q3 | $548K | Sell |
46,870
-3,639
| -7% | -$21.1K | ﹤0.01% | 6356 |
|
|
2017
Q2 | $184K | Buy |
50,509
+1,030
| +2% | +$3.95K | ﹤0.01% | 8354 |
|
|
2017
Q1 | $257K | Buy |
49,479
+26,352
| +114% | +$144K | ﹤0.01% | 7622 |
|
|
2016
Q4 | $110K | Buy |
+23,127
| New | +$126K | ﹤0.01% | 9036 |
|
|
2016
Q3 | – | Sell |
-28,774
| Closed | -$157K | – | 9207 |
|
|
2016
Q2 | $157K | Buy |
28,774
+5,573
| +24% | +$88.8K | ﹤0.01% | 7792 |
|
|
2016
Q1 | $497K | Sell |
23,201
-2,144
| -8% | -$47.9K | ﹤0.01% | 6410 |
|
|
2015
Q4 | $801K | Buy |
+25,345
| New | +$895K | ﹤0.01% | 5866 |
|
|
2015
Q3 | – | Sell |
-34,823
| Closed | -$1.05M | – | 10340 |
|
|
2015
Q2 | $1.1M | Buy |
+34,823
| New | +$1.03M | ﹤0.01% | 6020 |
|
Other funds holding MRTX
Susquehanna International Group's MRTX Position: Q1 2024 in Review
Susquehanna International Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 145,890 shares — an estimated $8.57M sold.
Susquehanna International Group first reported a position in MRTX in Q2 2015 and held it in 29 quarters. The position peaked at $15.7M in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Susquehanna International Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Susquehanna International Group sold 145,890 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $8.57M.
- Susquehanna International Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2015 and held it in 29 quarters.
- Susquehanna International Group's Mirati Therapeutics, Inc. Common Stock position peaked at $15.7M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.